Celularity (NASDAQ:CELU) Shares Down 3% – What’s Next?

Celularity, Inc. (NASDAQ:CELU)’s share price traded down 3% on Tuesday . The company traded as low as $3.14 and last traded at $3.19. 134,420 shares were traded during mid-day trading, a decline of 77% from the average session volume of 580,949 shares. The stock had previously closed at $3.29.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Celularity from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd.

Celularity Stock Performance

The company’s fifty day moving average price is $2.24 and its 200 day moving average price is $1.94. The company has a debt-to-equity ratio of 4.07, a current ratio of 0.38 and a quick ratio of 0.28. The company has a market cap of $76.40 million, a PE ratio of -1.20 and a beta of 0.74.

Celularity (NASDAQ:CELU) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.91. The business had revenue of $18.13 million during the quarter, compared to the consensus estimate of $5.20 million. Celularity had a negative net margin of 106.77% and a negative return on equity of 271.88%.

Hedge Funds Weigh In On Celularity

Large investors have recently modified their holdings of the company. Acadian Asset Management LLC bought a new stake in Celularity during the first quarter valued at approximately $34,000. Biltmore Family Office LLC bought a new stake in shares of Celularity during the 4th quarter valued at $73,000. Two Sigma Investments LP bought a new stake in shares of Celularity during the 4th quarter valued at $93,000. Valmark Advisers Inc. bought a new stake in shares of Celularity during the 2nd quarter valued at $98,000. Finally, C V Starr & Co. Inc. bought a new stake in shares of Celularity during the 4th quarter valued at $1,589,000. 19.02% of the stock is currently owned by institutional investors.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.